{"id":"placebo-to-bevacizumab","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab binds to VEGF-A with high affinity, preventing it from binding to its receptor on the surface of endothelial cells. This inhibits the formation of new blood vessels, which is a key process in tumor growth and metastasis. By inhibiting angiogenesis, bevacizumab can slow or stop the growth of certain types of cancer.","oneSentence":"Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:41.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Glioblastoma"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06703073","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-06-10","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":600},{"nctId":"NCT07284849","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-05","conditions":"CRC (Colorectal Cancer)","enrollment":700},{"nctId":"NCT05359861","phase":"PHASE2","title":"Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2022-04-12","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":"Colorectal Cancer, Metastatic Colon Cancer","enrollment":76},{"nctId":"NCT07323576","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-02-01","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT03778957","phase":"PHASE3","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-30","conditions":"Hepatocellular Carcinoma","enrollment":724},{"nctId":"NCT03602859","phase":"PHASE3","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2018-10-11","conditions":"Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","enrollment":1400},{"nctId":"NCT04982237","phase":"PHASE3","title":"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-08-27","conditions":"Cervical Cancer","enrollment":445},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT05377034","phase":"PHASE2","title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-10-26","conditions":"Locally Advanced Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT06471465","phase":"PHASE3","title":"Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-04-29","conditions":"Radionecrosis of Brain, Brain Metastases","enrollment":84},{"nctId":"NCT05690048","phase":"PHASE2","title":"Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)","status":"RECRUITING","sponsor":"Michael Dill","startDate":"2025-07-16","conditions":"Immunotherapy, HCC - Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT07025239","phase":"PHASE3","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Metastatic Colorectal Cancer","enrollment":430},{"nctId":"NCT04406272","phase":"PHASE2","title":"VB-111 in Surgically Accessible Recurrent/Progressive GBM","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":15},{"nctId":"NCT04856787","phase":"PHASE2, PHASE3","title":"A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-06-22","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":62},{"nctId":"NCT02641639","phase":"PHASE2, PHASE3","title":"FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Mateon Therapeutics","startDate":"2016-06","conditions":"Platinum Resistant Ovarian Cancer","enrollment":70},{"nctId":"NCT03737643","phase":"PHASE3","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-04","conditions":"Advanced Ovarian Cancer","enrollment":1407},{"nctId":"NCT06755515","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2024-09-26","conditions":"Cervical Cancer","enrollment":510},{"nctId":"NCT05322590","phase":"PHASE1, PHASE2","title":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bexion Pharmaceuticals, Inc.","startDate":"2023-01-09","conditions":"Metastatic Colorectal Carcinoma, Neuropathy","enrollment":195},{"nctId":"NCT06349980","phase":"PHASE2","title":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-08-05","conditions":"Carcinoma, Hepatocellular","enrollment":117},{"nctId":"NCT04607668","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity","enrollment":326},{"nctId":"NCT04227522","phase":"PHASE3","title":"Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients","status":"COMPLETED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2020-06-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":42},{"nctId":"NCT05118776","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-21","conditions":"Recurrent Glioblastoma","enrollment":136},{"nctId":"NCT04547166","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2021-03-10","conditions":"Metastatic Colorectal Cancer","enrollment":568},{"nctId":"NCT06642844","phase":"PHASE3","title":"Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-10-30","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":244},{"nctId":"NCT03635489","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-15","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":100},{"nctId":"NCT06099418","phase":"PHASE2","title":"Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.","status":"WITHDRAWN","sponsor":"Nykode Therapeutics ASA","startDate":"2024-04-18","conditions":"HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer","enrollment":""},{"nctId":"NCT06595355","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","status":"RECRUITING","sponsor":"Isfahan University of Medical Sciences","startDate":"2021-10-10","conditions":"Diabetic Macular Edema, Macular Edema, Retinal Neovascularization","enrollment":52},{"nctId":"NCT06349044","phase":"NA","title":"A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-03-20","conditions":"Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma","enrollment":120},{"nctId":"NCT05251727","phase":"PHASE1","title":"Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Veloxis Pharmaceuticals","startDate":"2022-03-24","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":77},{"nctId":"NCT06191094","phase":"PHASE4","title":"Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy","status":"ENROLLING_BY_INVITATION","sponsor":"University of Colorado, Denver","startDate":"2024-07-12","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus","enrollment":100},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT03117049","phase":"PHASE3","title":"Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-06-13","conditions":"Non-Small Cell Lung Cancer","enrollment":550},{"nctId":"NCT04460807","phase":"PHASE3","title":"Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer","status":"TERMINATED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2020-02-13","conditions":"Ovarian Cancer","enrollment":23},{"nctId":"NCT00942331","phase":"PHASE3","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-15","conditions":"Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma","enrollment":506},{"nctId":"NCT03952403","phase":"PHASE3","title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":643},{"nctId":"NCT04201561","phase":"PHASE3","title":"High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-12-24","conditions":"Chemotherapy-induced Peripheral Neuropathy, Recurrent Ovarian Carcinoma, Ovarian Cancer","enrollment":68},{"nctId":"NCT05798819","phase":"PHASE3","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2023-05-01","conditions":"Persistent, Recurrent, or Metastatic Cervical Cancer","enrollment":424},{"nctId":"NCT02490878","phase":"PHASE2","title":"Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2016-04","conditions":"Radionecrosis, Brain Metastases","enrollment":19},{"nctId":"NCT02659384","phase":"PHASE2","title":"Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2016-12-23","conditions":"Ovarian Neoplasms","enrollment":122},{"nctId":"NCT03038100","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1301},{"nctId":"NCT05715840","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-01-31","conditions":"Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","enrollment":368},{"nctId":"NCT05446883","phase":"PHASE3","title":"QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-09-23","conditions":"METASTATIC CERVICAL CANCER","enrollment":498},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT01609790","phase":"PHASE2","title":"Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-06-04","conditions":"Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma","enrollment":137},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT01468831","phase":"PHASE1, PHASE2","title":"Minocycline to Treat Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2012-03-28","conditions":"Retinal Vein Occlusion","enrollment":9},{"nctId":"NCT03905902","phase":"PHASE3","title":"DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","status":"WITHDRAWN","sponsor":"SOTIO a.s.","startDate":"2021-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT01507480","phase":"PHASE1","title":"The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-10","conditions":"Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic","enrollment":42},{"nctId":"NCT02389959","phase":"PHASE4","title":"Intranasal Bevacizumab for HHT-Related Epistaxis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-08-04","conditions":"HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis","enrollment":40},{"nctId":"NCT03037736","phase":"PHASE4","title":"Outpatient Performed Pterygium Surgery Study","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2020-03-01","conditions":"Pterygium of Conjunctiva and Cornea","enrollment":""},{"nctId":"NCT01468844","phase":"PHASE1, PHASE2","title":"Minocycline to Treat Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2011-12-21","conditions":"Retinal Vein Occlusion","enrollment":6},{"nctId":"NCT00130728","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-06-08","conditions":"Non-Small Cell Lung Cancer","enrollment":636},{"nctId":"NCT00536939","phase":"PHASE2","title":"Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT00612586","phase":"PHASE2","title":"Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-02","conditions":"Colorectal Cancer","enrollment":117},{"nctId":"NCT01501760","phase":"PHASE3","title":"Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2012-05-13","conditions":"Corneal Newvessels","enrollment":38},{"nctId":"NCT01403610","phase":"PHASE2","title":"Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-06","conditions":"HIGH GRADE GLIOMA","enrollment":28},{"nctId":"NCT00884741","phase":"PHASE3","title":"Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":637},{"nctId":"NCT00262847","phase":"PHASE3","title":"Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma","enrollment":1873},{"nctId":"NCT01663727","phase":"PHASE3","title":"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-08-27","conditions":"Metastatic Breast Cancer","enrollment":481},{"nctId":"NCT02305758","phase":"PHASE2","title":"Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-02","conditions":"Untreated Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT03607643","phase":"PHASE1, PHASE2","title":"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies","status":"UNKNOWN","sponsor":"Leaf Vertical Inc.","startDate":"2019-01-15","conditions":"Cancer of Pancreas, Cancer of Liver, Cancer of Rectum","enrollment":160},{"nctId":"NCT01860638","phase":"PHASE2","title":"A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-19","conditions":"Glioblastoma","enrollment":296},{"nctId":"NCT01632228","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-29","conditions":"Glioblastoma","enrollment":135},{"nctId":"NCT01364012","phase":"PHASE3","title":"A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-05-23","conditions":"Non-Small Cell Lung Cancer","enrollment":276},{"nctId":"NCT00911170","phase":"PHASE3","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-03","conditions":"Cancer, Colon Cancer, Colorectal Cancer","enrollment":847},{"nctId":"NCT00943826","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06-29","conditions":"Glioblastoma","enrollment":921},{"nctId":"NCT00434642","phase":"PHASE3","title":"A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-04","conditions":"Ovarian Cancer","enrollment":484},{"nctId":"NCT00486759","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-07-26","conditions":"B-cell Lymphoma","enrollment":787},{"nctId":"NCT00473590","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":102},{"nctId":"NCT00548548","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-09","conditions":"Adenocarcinoma","enrollment":774},{"nctId":"NCT00636610","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-05","conditions":"Metastatic Colorectal Cancer","enrollment":199},{"nctId":"NCT01493843","phase":"PHASE2","title":"Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01-20","conditions":"Non-Small Cell Lung Cancer","enrollment":501},{"nctId":"NCT00887822","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Gastric Cancer","enrollment":202},{"nctId":"NCT01186991","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-03","conditions":"Breast Cancer","enrollment":185},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00061178","phase":"PHASE3","title":"Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma","status":"WITHDRAWN","sponsor":"Genentech, Inc.","startDate":"","conditions":"Renal Cell Cancer","enrollment":""},{"nctId":"NCT01414153","phase":"PHASE2","title":"Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD","status":"COMPLETED","sponsor":"Lpath, Inc.","startDate":"2012-08","conditions":"Exudative Age-related Macular Degeneration","enrollment":158},{"nctId":"NCT00069095","phase":"PHASE3","title":"A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-07","conditions":"Colorectal Cancer","enrollment":2035},{"nctId":"NCT01399684","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-11","conditions":"Metastatic Colorectal Cancer","enrollment":127},{"nctId":"NCT00320255","phase":"PHASE2","title":"A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"Thrombosis, Cancer, Pulmonary Embolism","enrollment":130},{"nctId":"NCT02555800","phase":"PHASE2","title":"Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis","status":"UNKNOWN","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2014-12","conditions":"Recurrent Respiratory Papillomatosis","enrollment":36},{"nctId":"NCT01327794","phase":"","title":"Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2011-06","conditions":"Pancreatic Cancer","enrollment":265},{"nctId":"NCT00738530","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Renal Cell Cancer","enrollment":649},{"nctId":"NCT01314066","phase":"PHASE2","title":"Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2010-07","conditions":"Severe Sepsis, Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT00333775","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":"Breast Cancer","enrollment":736},{"nctId":"NCT00356681","phase":"PHASE2","title":"A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer","status":"TERMINATED","sponsor":"Amgen","startDate":"2006-12","conditions":"Breast Neoplasms, Breast Tumors, Breast Cancer","enrollment":282},{"nctId":"NCT01200121","phase":"PHASE2","title":"Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2010-02","conditions":"Malignant Ascites, Gastrointestinal Cancers","enrollment":53},{"nctId":"NCT00915603","phase":"PHASE2","title":"Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-07","conditions":"Metastatic Breast Cancer","enrollment":113},{"nctId":"NCT01214720","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Pancreatic Cancer","enrollment":607},{"nctId":"NCT00976677","phase":"PHASE2","title":"Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-01","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":10},{"nctId":"NCT00493636","phase":"PHASE2","title":"1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2007-06","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT00492089","phase":"PHASE2","title":"Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma","enrollment":11},{"nctId":"NCT00110214","phase":"PHASE3","title":"Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-04","conditions":"Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":1050},{"nctId":"NCT00625651","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10","conditions":"Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer","enrollment":202},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT00281697","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-02","conditions":"Metastatic Breast Cancer","enrollment":684},{"nctId":"NCT00889343","phase":"PHASE2","title":"Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2009-03","conditions":"Colorectal Neoplasms","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to bevacizumab","genericName":"Placebo to bevacizumab","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}